Valproate-associated Movement Disorder: A Literature Review
Open Access
- 3 October 2021
- journal article
- review article
- Published by Charles University in Prague, Karolinum Press in Prague Medical Report
- Vol. 122 (3), 140-180
- https://doi.org/10.14712/23362936.2021.14
Abstract
Valproate (VPA) was first synthesized in 1882, but it was only in the early 1960s that its anticonvulsant properties were discovered. The aim of this literature review is to evaluate the clinical epidemiological profile, pathological mechanisms, and management of VPA-associated movement disorder (MD). Relevant reports in six databases were identified and assessed by two reviewers without language restriction. A total of 138 reports containing 362 cases of subjects who developed a MD secondary to VPA were reported. The MD identified were parkinsonism (PKN) (252), myoclonus (MCL) (54), dystonia (DTN) (17), dyskinesia (DKN) (16), stutters (4), tics (3), akathisia (AKT) (1). In the not clearly defined group, 15 extrapyramidal symptoms, 3 AKT, 2 DTN, 1 rigidity, 1 unstable gait were assessed. The mean and median age was 55.8 (SD: 16.58) and 61 years (range: 4–87 years). The most common VPA-indication was epilepsy, and 51.36% were males. The mean and median time from the VPA start to the MD onset was 32.75 (SD: 30.05) and 21.15 months (range: 1 day – 20 years). The mean and median time from the VPA withdrawal until the MD recovery was 2.89 (SD: 2.79) and 3 months (1 day – 12 months). The most common management was drug withdrawal. A complete recovery was obtained in 80.61%. VPA-associated MD was extensively reported in the literature. PKN was the most well-described. Future studies need to clearly report the clinical history of the patient, considering the full investigation of other adverse events during their entire life.Keywords
This publication has 100 references indexed in Scilit:
- Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in FranceMovement Disorders, 2011
- Valproate‐induced reversible hemichoreaMovement Disorders, 2010
- Syndrome démentiel et extrapyramidal iatrogène : effet secondaire rare de l’association acide valproïque-aspirineLa Presse Médicale, 2010
- The relationship between uric acid levels and Huntington's disease progressionMovement Disorders, 2010
- Valproic Acid-Induced Myoclonus in a Demented Patient: A Case ReportCase Reports in Medicine, 2009
- Movement disorders in patients taking anticonvulsantsJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Valproate-Induced Chorea and Encephalopathy in Atypical Nonketotic HyperglycinemiaPediatric Neurology, 2006
- Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory studyMovement Disorders, 2002
- Adverse Response to Methylphenidate in Combination with Valproic AcidJournal of Child and Adolescent Psychopharmacology, 2000
- Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preferenceThe Journal of Pediatrics, 1992